- Home
- CURV vs SLN Comparison
CURV vs SLN Comparison
Compare CURV & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURV
- SLN
- Stock Information
- Founded
- CURV 2001
- SLN 1994
- Country
- CURV United States
- SLN United Kingdom
- Employees
- CURV N/A
- SLN N/A
- Industry
- CURV Clothing/Shoe/Accessory Stores
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- CURV Consumer Discretionary
- SLN Health Care
- Exchange
- CURV Nasdaq
- SLN Nasdaq
- Market Cap
- CURV 215.9M
- SLN 299.4M
- IPO Year
- CURV 2021
- SLN N/A
- Fundamental
- Price
- CURV $2.16
- SLN $4.81
- Analyst Decision
- CURV Hold
- SLN Buy
- Analyst Count
- CURV 4
- SLN 5
- Target Price
- CURV $4.00
- SLN $32.60
- AVG Volume (30 Days)
- CURV 482.6K
- SLN 61.8K
- Earning Date
- CURV 09-04-2025
- SLN 08-07-2025
- Dividend Yield
- CURV N/A
- SLN N/A
- EPS Growth
- CURV N/A
- SLN N/A
- EPS
- CURV 0.09
- SLN N/A
- Revenue
- CURV $1,089,931,000.00
- SLN $27,169,000.00
- Revenue This Year
- CURV N/A
- SLN N/A
- Revenue Next Year
- CURV N/A
- SLN N/A
- P/E Ratio
- CURV $24.08
- SLN N/A
- Revenue Growth
- CURV N/A
- SLN 22.28
- 52 Week Low
- CURV $2.08
- SLN $1.97
- 52 Week High
- CURV $7.25
- SLN $20.48
- Technical
- Relative Strength Index (RSI)
- CURV 35.39
- SLN 34.88
- Support Level
- CURV $2.13
- SLN $4.91
- Resistance Level
- CURV $2.24
- SLN $5.34
- Average True Range (ATR)
- CURV 0.10
- SLN 0.48
- MACD
- CURV 0.05
- SLN -0.05
- Stochastic Oscillator
- CURV 38.30
- SLN 0.71
About CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand of apparel, intimates, and accessories in North America. The company is focused on fit and offers high-quality products across a broad assortment that includes tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of the e-commerce platform and stores. The company generates revenue from the sale of apparel, intimates, and accessories through its e-commerce platform and its store locations.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.